Pelvic exenteration: a review of the Gateshead experience 1974-1992.
OBJECTIVE
To examine morbidity and survival among women treated by pelvic exenteration for gynaecological malignancy.


METHODS
Retrospective review by analysis of case records.


METHODS
Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead, UK.


METHODS
Eighty-three consecutive patients referred from within the UK from 1974 to 1992 for initial treatment of advanced gynaecological malignancy or management of recurrent disease following unsuccessful initial therapy.


RESULTS
Overall five year actuarial survival was 41%, falling to 36% at 10 years. Serious morbidity was low, and there were only three peri-operative deaths.


CONCLUSIONS
For patients with limited options for treatment of advanced primary or recurrent cancer, exenteration offers a reasonable prospect of survival with good quality of life.
Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead, Tyne, UK.
G
G
Robertson
A
A
Lopes
G
G
Beynon
J M
JM
Monaghan
D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000401:mortality*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality*; D004739:England / Q000453:epidemiology; D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality* / Q000601:surgery; D006801:Humans; D007414:Intestinal Neoplasms / Q000401:mortality / Q000601:surgery; D007420:Intestine, Large / Q000601:surgery; D007902:Length of Stay; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010385:Pelvic Exenteration / Q000009:adverse effects / Q000401:mortality*; D012189:Retrospective Studies; D016019:Survival Analysis